Business
£40.0m Equity Issuance and £29.4m Secondary S...
£40.0m Equity Issuance and £29.4m Secondary S....
About this update from 4basebio Plc
[{"type":"text","content":"\n\n \n \n\n\n\n\nThis Announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation No. 596/2014 as retained as part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended (\"EUWA\") and as it may be modified from time to time by or under domestic law including, but not limited to, by the Market Abuse (Amendment) (EU Exit) Regulations 2019/310). Upon the publication of this Announcement, this inside information is now considered to be in the public domain.29 July 20244basebio PLC Announces £40.0 million Equity Issuance and £29.4 million Secondary SaleJuly 29, 2024 - 4basebio PLC (AIM: 4BB) (\"4basebio\" or the \"Company\"), which develops and commercialises the large scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announces that it has agreed to binding terms with (i) Elevage Medical Technologies (\"Elevage\"), a Patient Square Capital platform and (ii) Prudential Assurance Company Limited acting by its investment manager M&G Investment Management Limited (\"M&G\"), for a combined investment of £40.0 million through an issuance (the \"Issuance\") of ordinary shares of €1 each at an issue price of 1,500 pence per Ordinary Share (the \"Issue Price\"). Net proceeds from the Issuance will be used to support and expand the Company's operations; including building out business development and commercial functions, enhancing the Company's infrastructure, driving continued innovation in new DNA modalities and supporting geographical expansion, in addition to working capital.The shares to be issued pursuant to the Issuance (the \"Issuance Shares\") will represent approximately 20.8 per cent. of the existing issued ordinary share capital of the Company and 17.2 per cent. of the enlarged issued ordinary share capital of the Company following completion of the Issuance (on the basis of the Company's issued share capital as at the date of this announcement). The Issue Price represents a premium of approximately 3.4 per cent. to the closing price of 1,450 pence per share on 26 July 2024, being the latest practicable date prior to the publication of this announcement (the \"Announcement\").In addition, Elevage and M&G have between them agreed to purchase 1,959,424 ordinary shares from entities belonging to the Deuts...